ILD Clinical Trials
Study Investigators:
Dr. Jesse Roman
Dr. Rafael Perez
► Ask a question about ILD clinical trials at the University of Louisville
- FG 3019-049: A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor
Fibrogen, Inc.
Purpose
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Study Drug
Experimental; Study Drug (FG-3019) intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
Status
Active, not recruiting
More information from clinicaltrials.gov
- FG 3019-067: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor
Fibrogen, Inc.
Purpose
To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.
Study Drug
Experimental; FG-3019 or placebo by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
Status
Active, recruiting
More information from clinicaltrials.gov
- PIPF 016: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
Sponsor
InterMune, Inc.
Purpose
The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.
Study Drug
Experimental Drug; Pirfenidone or Placebo, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
Status
Completed, awaiting results
More information from clinicaltrials.gov
- PIPF 012: An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor
InterMune, Inc.
Purpose
This is an open-label, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
Status
Active, not recruiting
More information from clinicaltrials.gov
- RANIER STUDY: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor
Gilead Sciences
Purpose
The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis
Study Drug
Experimental; Simtuzumab (GS-6624) or Placebo,125 mg/mL, single dose vials, subcutaneous self-injection, once weekly
Status
Active, recruiting
More information from clinicaltrials.gov
- BMS IM136003 IPF Study: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Sponsor
BristolMyersSquibb
Purpose
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).
Study Drug
Experimental; BMS 986020 and/or placebo, 600 mg tablets, taken by mouth, twice daily, 26 weeks
Status
Active, recruiting
More information from clinicaltrials.gov
- BRAVE 3: Bronchial Sample Collection for a Novel Genomic Test – 3
Sponsor
Veracyte, Inc.
Purpose
This is a specimen and data collection study that is being done to see if researchers can develop a better test by using genes found in the body to more accurately diagnose the different types of pulmonary fibrosis.
Status
Active, recruiting
- PFF Registry
Sponsor: Pulmonary Fibrosis Foundation
Status: Draft stage
- IPF PRO: Prospective Outcomes Registry of Subjects With Idiopathic Pulmonary Fibrosis
Sponsor
Boehringer Ingelheim
Purpose
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts.
Status
Active, recruiting
